Hypercholesterolemia Global Market Report 2025

The hypercholesterolemia market size has grown rapidly in recent years. It will grow from $16.3 billion in 2024 to $18.66 billion in 2025 at a compound annual growth rate (CAGR) of 14.5%. The growth during the historic period can be attributed to several factors, including the rise of health campaigns, increased investment in research and development, a growing emphasis on preventive healthcare, and the expansion of preventive health screenings alongside lifestyle modifications.

The hypercholesterolemia market size is expected to see rapid growth in the next few years. It will grow to $31.7 billion in 2029 at a compound annual growth rate (CAGR) of 14.2%. The growth during the forecast period can be attributed to factors such as improved diagnosis and screening, government initiatives and health policies, the growing prevalence of risk factors, the increasing availability of over-the-counter (OTC) cholesterol-lowering products, and heightened awareness of cholesterol-related risks. Key trends include advancements in lipid profiling, the use of robotic-assisted surgeries, the application of nanotechnology in drug delivery, the rise of telemedicine platforms, and the focus on lipoprotein targeting.

The growing prevalence of cardiovascular diseases is expected to drive the growth of the hypercholesterolemia market in the coming years. Cardiovascular diseases (CVDs) are a group of disorders affecting the heart and blood vessels. The rise in cardiovascular diseases is largely due to unhealthy diets, physical inactivity, increasing obesity rates, chronic stress, aging populations, and the prevalence of conditions such as hypertension and diabetes. Hypercholesterolemia treatments help cardiovascular disease patients by lowering LDL cholesterol levels, reducing plaque buildup in the arteries, improving blood flow, and decreasing the risk of heart attacks, strokes, and other cardiovascular complications. For instance, in October 2024, the Centers for Disease Control and Prevention reported that around 805,000 people in the United States experience a heart attack each year, with 605,000 being first-time incidents and 200,000 occurring in individuals with a history of previous heart attacks. Therefore, the rising incidence of cardiovascular diseases is expected to propel the hypercholesterolemia market.

Key players in the hypercholesterolemia market are developing innovative products, such as triple-combination drugs, to improve treatment efficacy and enhance patient compliance. A triple-combination drug combines three active ingredients into a single dosage form, such as a tablet or capsule. For example, in February 2025, Celltrion Pharm, Inc., a South Korea-based pharmaceutical company, launched Amrozet Tablet, a drug for hypertension and hyperlipidemia. This medication combines three active ingredients such as amlodipine, a calcium channel blocker for hypertension; rosuvastatin, a statin to lower cholesterol; and ezetimibe, which helps reduce cholesterol absorption in the intestines. The drug is available in four dosage combinations (5/5/10 mg, 5/10/10 mg, 10/5/10 mg, and 10/10/10 mg) and is indicated for hypertension and myocardial ischemia under amlodipine, primary hypercholesterolemia under the rosuvastatin-ezetimibe combination, and also for relieving chronic stable angina or vasospastic angina. Additionally, it helps reduce the risk of hospitalization for angina and heart surgery in patients with documented coronary artery disease.

In August 2023, HDL Therapeutics, Inc., a U.S.-based biotechnology company, merged with Swiftmerge Acquisition Corp. for an undisclosed amount. This merger aims to accelerate the commercialization of HDL Therapeutics' FDA-approved Plasma Delipidation System (PDS-2) for treating patients with homozygous familial hypercholesterolemia (HoFH). Swiftmerge Acquisition Corp. is a U.S.-based special purpose acquisition company (SPAC) focused on providing treatment for HoFH.

Major players in the hypercholesterolemia market are Pfizer Inc., Merck & Co Inc., Abbvie Inc., Bayer AG, Sanofi S.A., AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Amgen Inc., Viatris Inc., Aegerion Pharmaceuticals Inc., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Chiesi Farmaceutici S.p.A., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Lupin Limited, Ionis Pharmaceuticals Inc., Melinta Therapeutics Inc., NewAmsterdam Pharma N.V., HDL Therapeutics Inc.

North America was the largest region in the hypercholesterolemia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hypercholesterolemia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hypercholesterolemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Hypercholesterolemia refers to an abnormally high level of cholesterol in the blood, particularly low-density lipoprotein (LDL) cholesterol, which increases the risk of atherosclerosis and cardiovascular diseases such as heart attacks and strokes. It is often influenced by genetic factors, poor diet, lack of physical activity, and underlying health conditions such as diabetes or hypothyroidism.

The primary types of hypercholesterolemia are genetic and acquired. Genetics refers to the study of genes, heredity, and the variation of inherited traits in living organisms, which play a crucial role in determining susceptibility to various conditions, including familial hypercholesterolemia. Treatment for hypercholesterolemia includes statins, bile acid resins, niacin, PCSK9 inhibitors, cholesterol absorption inhibitors, fibric acid derivatives, and other medications. These treatments are available in oral and injectable forms. They are distributed through various channels, such as hospital pharmacies, retail pharmacies, and other outlets, and are used by a wide range of end users, including hospitals, specialty clinics, home healthcare providers, and others.

The hypercholesterolemia market research report is one of a series of new reports that provides hypercholesterolemia market statistics, including hypercholesterolemia industry global market size, regional shares, competitors with a hypercholesterolemia market share, detailed hypercholesterolemia market segments, market trends and opportunities, and any further data you may need to thrive in the hypercholesterolemia industry. This hypercholesterolemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hypercholesterolemia market consists of sales of omega-3 fatty acid supplements, atorvastatin, and simvastatin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.